Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent

American Journal of Cardiology

Volumn 78, Issue 4 A, 1996, Pages 41-53

  Singh, Bramah N ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TOCAINIDE;

ANTIARRHYTHMIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEART DEATH; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; MYOPATHY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029801247     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00452-3     Document Type: Conference Paper

References (64)

1. Charlier R, Deltour G, Baudine A. Pharmacology of amiodarone, an antianginal drug with a new biological profile. Arzneimittelforsch 1968;18:1408-1421.
2. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 1970;39:657-667.
3. Rosenbaum MB, Chiale PA, Ryba D, Elizari MV. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol 1974;34:215-222.
4. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari M. Clinical efficacy of amiodarone as an anti-arrhythmic agent. Am J Cardiol 1976;38:934-942.
5. Singh BN. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol 1996;78(suppl 4A):17-27.
6. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106:788-797.
7. Singh BN. Advantages of β blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. Am J Cardiol 1990;66(suppl):9C-20C.
8. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observations relative to serum and tissue concentrations. Am Heart J 1984;108:890-899.
9. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR, for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-3272.
10. Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM, for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation 1995;92:3255-3263.
11. Pritchard DA, Singh BN, Hurley PJ. Effects of amiodarone on thyroid function in patients with ischemic heart disease. Br Heart J 1975;37:856-860.
12. Antimisiaris M, Sarma JSM, Schoenbaum MP, Sharma PP, Venkataraman K, Singh BN. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval. Significance for the control of sudden cardiac death. Am Heart J 1994;128:884-891.
13. Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120-124.
14. Morady F, DiCarlo LA, Krol RB, Baerman JM, de Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986;7:148-157.
15. Shenasa M, Denker S, Mahmud R, Lehmann M, Estrada A, Akhtar M. Effect of amiodarone on conduction and refractoriness of the His-Purkinje system in the human heart. J Am Coll Cardiol 1984;4:105-110.
16. Singh BN. Electropharmacology of amiodarone. In: Vaughan Williams EM, Campbell TJ, eds. Anti-arrhythmic Drugs. Berlin: Springer-Verlag, 1988:335-364.
17. Cui G, Sen L, Sager P, Uppal P, Singh BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74:896-900.
18. Holnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.
19. Côtè P, Bourassa MG, Delaye J, Janin A, Froment R, David P. Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation 1979;59:1165-1173.
20. Singh SN, Fletcher RD, Gross Fisher S, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling CC, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
21. Ammar A, Wong M, Singh BN. Divergent effects of chronic amiodarone administration on systolic and diastolic function in patients with heart disease. Am J Cardiol 1995;75:465-469.
22. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989;14:1768-1774.
23. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994;19:12-22.
24. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-1071.
25. Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 1990;15:213-221.
26. Salerno D, Gillingham KJ, Berry DA, Hodges M. A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarization. A meta-analysis. Am Heart J 1990;120:340-353.
27. Mason JW. Amiodarone. N Engl J Med 1987;316:455-466.
28. Nademanee K, Singh BN, Hendrickson J, Intarachot V, Lopez B, Feld G, Cannom DS, Weis JN. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 1983;98:577-584.
29. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, Goldberg H, Scheinman MM. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-449.
30. Weinberg BA, Miles WM, Klein LS, Zipes DP. Five year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120.
31. Nasir N, Swarna US, Boehene KA, Doyle TK, Pacifico A. Therapy of sustained ventricular arrhythmias with amiodarone: prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Ther 1996;1:123-132.
32. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993;72:280-287.
33. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-451.
34. Singh BN. Implantable cardioverter-defibrillators: not the ultimate gold standard for gauging therapy of VT/fibrillation? Am J Cardiol 1994;73:1211-1213.
35. Zipes DP. Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation 1995;91:2115-2117.
36. Kim SG. Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol 1993;71:1213-1218.
37. Kulkamp V, Mermi J, Mewis C, Braun U, Seipel L. Does programmed electrical stimulation predict long term efficacy of dl-sotalol? Circulation 1994;90:I-545.
38. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, the CASH Investigators. Preliminary results of the cardiac arrest study Hamburg (CASH). Am J Cardiol 1993;72(suppl):109F-113F.
39. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D, on behalf of the CIDS Co-Investigators. Canadian implantable defibrillator study (CIDS): study design and organization. Am J Cardiol 1993;72(suppl):103F-108F.
40. Kim SG. Evaluation of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators. Am Heart J 1995;130:1144-1150.
41. McKenna WJ, Adams KM, Poloniecki JD, Dickie S, Oakley CM, Krikler DM, Goodwin JF. Long term survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Circulation 1989;80:II-7.
42. Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation 1992;85(suppl I):I57-I63.
43. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation 1993;88:764-774.
44. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718.
45. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
46. Pfisterer ME, Kiowski W, Brunner H, Burkhardt D, Burkart F. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993;87:309-311.
47. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-557.
48. Camm AJ, Julian D, Janse G, Munoz A, Schwartz P, Simon P, Frangin G. For the European Myocardial Infarct Amiodarone Trial (EMIAT) Investigators. Am J Cardiol 1993;72(suppl):95F-98F.
49. Holmes J, Kubo S, Cody R , Kligfield P. Arrhythmias in ischemia and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985;55:146-151.
50. Meinertz TM, Hofmann T, Kasper W, Treese N, Bechtold H, Stienen U, Pop T, Leitner EV, Andresen D, Meyer J. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984;53:902-907.
51. Von Olshausen K, Schafer A, Mehmel HC, Schwarz F, Senges J, Kübler W. Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J 1984;51:195-201.
52. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) Investigators. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
53. CIBIS Investigators and Committees. A randomized trial of (β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
54. Olsson SB, Brorson L, Varnauskas E. Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br Heart J 1973;35:1255-1259.
55. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983;106:870-875.
56. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
57. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-1407.
58. Brodsky MA, Allen BJ, Walker CJ III, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
59. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, Rubenfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987;147:1401-1404.
60. Vitolo E, Tronçi M, Larovere MT, Rumolo R, Morabito A. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36:431-444.
61. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 1992;116:1017-1020.
62. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
63. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
64. Disch DL, Greenberg ML, Holzberger PT, Malenka DJ, Birkmeyer JD. Managing atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994;120:449-457.